: BioXcel Therapeutics shares pop after audit of Alzheimer’s trial data

Audit findings support application for approval of treatment for Alzheimer’s-related agitation, company says

Previous post : Vertiv stock rallies as data company beats profit expectation and hikes view
Next post Futures Movers: Oil prices tread water after wiping out more than half of October’s gains